Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

THERMO FISHER SCIENTIFIC

(TMO)
  Report
Delayed Nyse  -  04:00 2022-09-27 pm EDT
508.66 USD   -1.10%
09/22Thermo Fisher Scientific Partners with Pennsylvania Biotechnology Center to Support Life Sciences Growth in Philadelphia
AQ
09/21Thermo Fisher Scientific Opens Biomanufacturing Facility in Massachusetts
MT
09/20Thermo Fisher Scientific : Invests $160 Million to Expand Bioproduction Capacity in Greater Boston
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Introduces Highly Sensitive Research Assays for Measurable Residual Disease Detection in Myeloid Malignancies

08/04/2022 | 08:30am EDT

Thermo Fisher Scientific launched a next-generation sequencing (NGS)-based assay for research in myeloid measurable residual disease (MRD). As the first NGS-based tests to support both DNA and RNA input, the Ion Torrent Oncomine Myeloid MRD Assays (RUO) provide a comprehensive and highly sensitive MRD assessment from blood and bone marrow samples. Acute myeloid leukemia (AML) is characterized by rapid disease progression and can be fatal if not treated promptly.

Depending on their interventions, the number of AML patients who experience relapsed disease can be as high 78%. Detecting remaining mutations after treatment can help identify the presence of residual disease and guide patient prognosis and further treatment decisions. This is driving a growing need for an MRD detection methods that can simultaneously track mutations across multiple genes with high sensitivity.

Current MRD detection methods do not evaluate individual mutations or can only track a very limited number at once. Thermo Fisher's Myeloid MRD Assay has been designed to enable simultaneous testing and identification of more than 90% of common AML mutations and fusions, providing insights to guide the future of clinical applications, standards and drug development. The Myeloid MRD Assay enables sensitive variant detection as low as 0.05% allele frequency for key DNA mutations in 33 genes and evaluation of more than 900 isoforms in 43 RNA fusion driver genes – including many targets for which there are no established assays to-date.

The end-to-end workflow delivers results in as little as two days with an integrated informatics pipeline and reporting tool that can help to minimize user hands-on time and speed up time to results.


© S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
09/22Thermo Fisher Scientific Partners with Pennsylvania Biotechnology Center to Support Lif..
AQ
09/21Thermo Fisher Scientific Opens Biomanufacturing Facility in Massachusetts
MT
09/20Thermo Fisher Scientific : Invests $160 Million to Expand Bioproduction Capacity in Greate..
PU
09/14THERMO FISHER SCIENTIFIC : Ex-dividend day for
FA
09/13Thermo Fisher Scientific Collaborates with Taiwan Precision Medicine Initiative to Geno..
CI
09/12Barclays Cuts Thermo Fisher Scientific's Price Target to $595 From $685, Keeps Overweig..
MT
09/12Transcript : Thermo Fisher Scientific Inc. Presents at Morgan Stanley 20th An..
CI
09/12Thermo Fisher Scientific Certifies Applies Biosystems QuantStudio 7 Pro Dx Real-Time PC..
CI
09/07Thermo Fisher Scientific to Present at Morgan Stanley 2022 Global Healthcare Conference
BU
08/30Thermo Fisher Scientific Launches CE-IVD Next-Generation Sequencing Test and Analysis S..
AQ
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 199 M - -
Net income 2022 6 924 M - -
Net Debt 2022 24 596 M - -
P/E ratio 2022 29,1x
Yield 2022 0,23%
Capitalization 199 B 199 B -
EV / Sales 2022 5,18x
EV / Sales 2023 4,97x
Nbr of Employees 130 000
Free-Float 88,7%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 508,66 $
Average target price 658,24 $
Spread / Average Target 29,4%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC-21.95%201 501
DANAHER CORPORATION-20.17%191 071
INTUITIVE SURGICAL, INC.-47.70%67 112
BOSTON SCIENTIFIC CORPORATION-8.43%54 917
EDWARDS LIFESCIENCES CORPORATION-35.48%51 821
SIEMENS HEALTHINEERS AG-36.49%45 093